Obermeyer Wealth Partners’s Lucid Diagnostics LUCD Stock Holding History

Obermeyer Wealth Partners’s Portfolio LUCD Stock Details LUCD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$14.9K	Hold	13,000	–	–	﹤0.01%	299
2025 Q4	$14.2K	Hold	13,000	–	–	﹤0.01%	289
2025 Q3	$13.1K	Hold	13,000	–	–	﹤0.01%	294
2025 Q2	$14.9K	Hold	13,000	–	–	﹤0.01%	277
2025 Q1	$19.4K	Buy	+13,000	New	+$15.6K	﹤0.01%	260

Other funds holding LUCD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

MCM

Masters Capital Management Atlanta, Georgia $3.03B AUM 57.21% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return

Obermeyer Wealth Partners's LUCD Position: Q1 2026 in Review

Obermeyer Wealth Partners held its Lucid Diagnostics (LUCD) position steady in Q1 2026 at 13,000 shares worth $14.9K. The position accounts for ﹤0.01% of the portfolio, ranked #299.

Obermeyer Wealth Partners first reported a position in LUCD in Q1 2025 and has held it in 5 quarters since. The position peaked at $19.4K in Q1 2025. 103 funds tracked by Wall St. Rank hold LUCD as of Q1 2026.

Obermeyer Wealth Partners held 13,000 shares of Lucid Diagnostics worth $14.9K as of Q1 2026.
Obermeyer Wealth Partners left its Lucid Diagnostics share count unchanged in Q1 2026.
Lucid Diagnostics made up ﹤0.01% of Obermeyer Wealth Partners's portfolio in Q1 2026, its #299 holding.
Obermeyer Wealth Partners first reported a position in Lucid Diagnostics in Q1 2025 and has held it in 5 quarters since.
Obermeyer Wealth Partners's Lucid Diagnostics position peaked at $19.4K in Q1 2025.
103 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q1 2026.

Based on Obermeyer Wealth Partners's 13F filing for Q1 2026, filed 21 Apr 2026.